论文部分内容阅读
美国FDA于2012年11月29日批准Cometriq(cabozantinib)用于治疗已经转移的甲状腺髓样癌。甲状腺的主要功能是分泌降钙素以调节血液中的钙。甲状腺髓样癌可自然发生,也可能因家族基因变异而引起。据美国国立癌症研究院(NCI)估计,2012年全美国约有56 460人诊断出患甲状腺癌,约1 780人将因此死
US FDA approved Cometriq (cabozantinib) on November 29, 2012 for the treatment of medullary thyroid carcinoma that has metastasized. The main function of the thyroid is to secrete calcitonin to regulate the calcium in the blood. Medullary thyroid carcinoma can occur spontaneously, may also be caused due to changes in the family of genes. According to the National Cancer Institute (NCI), an estimated 56,460 people worldwide diagnosed with thyroid cancer in 2012 and about 1,780 people will die